LeadDiscovery

LeadDiscovery was founded in 1998 by life scientists for life scientists. Based on a solid background of experience from within pharmaceutical R&D our aim is to help companies develop their pipelines through the identification of breaking research and the in depth and expert evaluation of selected therapeutic areas. At the same time we provide a showcase for organizations wishing to increase the exposure of their research to the drug development community. We support the drug discovery and development community through two key services: DailyUpdates & PharmaReports
 

List of reports from LeadDiscovery

UpdatesPlus-Nicotinic Receptors
2/20/2008 | published by: LeadDiscovery
... month, as usual we provide a fully up to date snapshot of the nicotinic receptor ligand pipeline. In addition we report on breaking activity: Memory Pharmaceuticals' phase 2a study of MEM 3454 in CIAS Research ...  |  more...
$10,000.00
Pipeline Report - Neuronal alpha 7 nicotinic receptors: Candidates for the treatment of Alzheimers disease and Schizophrenia
12/1/2007 | published by: LeadDiscovery
... this class and analyzes the various different pharmacological approaches. The report evaluates the á7nAChR pipeline. Preclinical and clinical stages candidates are identified and experimental data surrounding their development described and analyzed. In addition the companies ...  |  more...
$3,000.00
Coxibs - Past Problems...Future Potential
10/1/2006 | published by: LeadDiscovery
... first Coxib, Celebrex (celecoxib), arrived on the market in 1998 rapidly becoming a blockbuster soon to be followed by another equally successful drug from the same class, Vioxx (rofecoxib). Soon after however, cardiovascular adverse effects ...  |  more...
$1,045.00
Aurora Kinase Inhibitors: The Dawn Of A New Approach To Cancer
5/1/2006 | published by: LeadDiscovery
... formation as exemplified by the alkaloids. Recently a new approach to cell cycle regulation has emerged with the identification of the Aurora kinase family. This family plays a role in later stages of the cell ...  |  more...
$665.00
Ventricular Fibrillation and Atrial Fibrillation : Emerging Antiarrhythmics In The Context of Current Devices, Interventions and Pharmacological Agents
5/1/2006 | published by: LeadDiscovery
... notably Cardiome’s RSD1235, paving the way for development by others. This report discusses current pharmacological and interventional treatments of ventricular and atrial fibrillation paying especial attention to unmet needs and drivers of future development. The ...  |  more...
$2,497.00
BAFF (BLys) & APRIL: Emerging Targets For Autoimmune Disease & Cancer Therapeutics
1/1/2006 | published by: LeadDiscovery
... development personnel up to speed in this area Proof of concept for developing blockers of BAFF and/or APRIL. CD70, a homologue of these proteins, and it’s receptor CD27 are also evaluated briefly. Identification of target ...  |  more...
$850.00
Autoimmune Disorders & Transplant Rejection The Potential Of T-cells Targeted Therapeutics
12/1/2005 | published by: LeadDiscovery
... large number of different conditions of varying prevalence, associated morbidity and disability, and available clinical options. Despite the fragmentation of this market it has proved lucrative for the drug development sector with the emergence of ...  |  more...
$2,241.00
Histone Deacetylase Inhibitors Moving From The Bench To A Promising Companion For Classic And Targeted Cancer therapies
5/1/2005 | published by: LeadDiscovery
... started to produce success in the clinic, particularly in the field of oncology. Over the next few years experts believe that as first generation HDAC inhibitors produce clinical benefits and second generation inhibitors are rationally ...  |  more...
$665.00
Rheumatoid Arthritis: Emerging Drug Discovery Targets And Therapeutic Candidates
10/1/2003 | published by: LeadDiscovery
... used to treat autoimmune disease will exceed $20 billion in the next few years. Rheumatoid arthritis is one of the more common and difficult to treat autoimmune diseases and there is a great deal of ...  |  more...
$712.00
Asthma Therapeutics: New Treatment Options And Emerging Drug Discovery Targets
4/1/2003 | published by: LeadDiscovery
... for oral treatment which will further improve patient compliance and possibly offer improved efficacy to treatment resistant patients. This report evaluates over 30 major therapeutic targets currently under investigation offering an expert view of the ...  |  more...
$627.00
Retinoids : An A-Z Guide To Their Biology, Therapeutic Opportunities & Pharmaceutical Development
2/1/2003 | published by: LeadDiscovery
... in current use are effective in only a small number of cancers as well as acne and psoriasis. Extending this benefit to other types of cancer as well as newer indications such as diabetes and ...  |  more...
$627.00
 

Research assistance

We can help you find what you need. Call us or write us:
US: 800.298.5699
Int'l: +1.240.747.3093
Need help in your search?
 

Join Alert Me now!

Receive bi-weekly email alerts on new market research

Sign up today!